BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 32340793)

  • 1. Synthetic bioactive olivetol-related amides: The influence of the phenolic group in cannabinoid receptor activity.
    Brizzi A; Aiello F; Boccella S; Cascio MG; De Petrocellis L; Frosini M; Gado F; Ligresti A; Luongo L; Marini P; Mugnaini C; Pessina F; Corelli F; Maione S; Manera C; Pertwee RG; Di Marzo V
    Bioorg Med Chem; 2020 Jun; 28(11):115513. PubMed ID: 32340793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-affinity relationships and pharmacological characterization of new alkyl-resorcinol cannabinoid receptor ligands: Identification of a dual cannabinoid receptor/TRPA1 channel agonist.
    Brizzi A; Aiello F; Marini P; Cascio MG; Corelli F; Brizzi V; De Petrocellis L; Ligresti A; Luongo L; Lamponi S; Maione S; Pertwee RG; Di Marzo V
    Bioorg Med Chem; 2014 Sep; 22(17):4770-83. PubMed ID: 25065940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New resorcinol-anandamide "hybrids" as potent cannabinoid receptor ligands endowed with antinociceptive activity in vivo.
    Brizzi A; Brizzi V; Cascio MG; Corelli F; Guida F; Ligresti A; Maione S; Martinelli A; Pasquini S; Tuccinardi T; Di Marzo V
    J Med Chem; 2009 Apr; 52(8):2506-14. PubMed ID: 19331413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro and in vivo pharmacology of synthetic olivetol- or resorcinol-derived cannabinoid receptor ligands.
    Cascio MG; Bisogno T; Palazzo E; Thomas A; van der Stelt M; Brizzi A; de Novellis V; Marabese I; Ross R; van de Doelen T; Brizzi V; Pertwee R; Maione S; Di Marzo V
    Br J Pharmacol; 2006 Oct; 149(4):431-40. PubMed ID: 16953186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First "hybrid" ligands of vanilloid TRPV1 and cannabinoid CB2 receptors and non-polyunsaturated fatty acid-derived CB2-selective ligands.
    Appendino G; Cascio MG; Bacchiega S; Moriello AS; Minassi A; Thomas A; Ross R; Pertwee R; De Petrocellis L; Di Marzo V
    FEBS Lett; 2006 Jan; 580(2):568-74. PubMed ID: 16406364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopamides, vanillylamides, ethanolamides, and arachidonic acid amides of anti-inflammatory and analgesic drug substances as TRPV1 ligands.
    Sinning C; Watzer B; De Petrocellis L; Di Marzo V; Imming P
    ChemMedChem; 2008 Dec; 3(12):1956-64. PubMed ID: 19003845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conformationally constrained fatty acid ethanolamides as cannabinoid and vanilloid receptor probes.
    Appendino G; Ligresti A; Minassi A; Cascio MG; Allarà M; Taglialatela-Scafati O; Pertwee RG; De Petrocellis L; Di Marzo V
    J Med Chem; 2009 May; 52(9):3001-9. PubMed ID: 19361197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The multiplicity of spinal AA-5-HT anti-nociceptive action in a rat model of neuropathic pain.
    Malek N; Kostrzewa M; Makuch W; Pajak A; Kucharczyk M; Piscitelli F; Przewlocka B; Di Marzo V; Starowicz K
    Pharmacol Res; 2016 Sep; 111():251-263. PubMed ID: 27326920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vascular pharmacology of a novel cannabinoid-like compound, 3-(5-dimethylcarbamoyl-pent-1-enyl)-N-(2-hydroxy-1-methyl-ethyl)benzamide (VSN16) in the rat.
    Hoi PM; Visintin C; Okuyama M; Gardiner SM; Kaup SS; Bennett T; Baker D; Selwood DL; Hiley CR
    Br J Pharmacol; 2007 Nov; 152(5):751-64. PubMed ID: 17891160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigations on the 4-quinolone-3-carboxylic acid motif. 3. Synthesis, structure-affinity relationships, and pharmacological characterization of 6-substituted 4-quinolone-3-carboxamides as highly selective cannabinoid-2 receptor ligands.
    Pasquini S; Ligresti A; Mugnaini C; Semeraro T; Cicione L; De Rosa M; Guida F; Luongo L; De Chiaro M; Cascio MG; Bolognini D; Marini P; Pertwee R; Maione S; Di Marzo V; Corelli F
    J Med Chem; 2010 Aug; 53(16):5915-28. PubMed ID: 20718492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human brain endothelium: coexpression and function of vanilloid and endocannabinoid receptors.
    Golech SA; McCarron RM; Chen Y; Bembry J; Lenz F; Mechoulam R; Shohami E; Spatz M
    Brain Res Mol Brain Res; 2004 Dec; 132(1):87-92. PubMed ID: 15548432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-cannabinoid CB1, non-cannabinoid CB2 antinociceptive effects of several novel compounds in the PPQ stretch test in mice.
    Haller VL; Cichewicz DL; Welch SP
    Eur J Pharmacol; 2006 Sep; 546(1-3):60-8. PubMed ID: 16919265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TRPV1 modulators: Synthesis and in vitro evaluation of 1-heteroaryl piperidinecarboxamide and piperazinylurea derivatives.
    Congiu C; Onnis V; Balboni G; Schiano-Moriello A; Di Marzo V; De Petrocellis L
    Eur J Med Chem; 2015 Jul; 100():129-38. PubMed ID: 26079089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis, and binding studies of new potent ligands of cannabinoid receptors.
    Brizzi A; Brizzi V; Cascio MG; Bisogno T; Sirianni R; Di Marzo V
    J Med Chem; 2005 Nov; 48(23):7343-50. PubMed ID: 16279794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis, biological activity and molecular modeling of new biphenylic carboxamides as potent and selective CB2 receptor ligands.
    Bertini S; Parkkari T; Savinainen JR; Arena C; Saccomanni G; Saguto S; Ligresti A; Allarà M; Bruno A; Marinelli L; Di Marzo V; Novellino E; Manera C; Macchia M
    Eur J Med Chem; 2015 Jan; 90():526-36. PubMed ID: 25486424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-activity relationships defining the ACD-tricyclic cannabinoids: cannabinoid receptor binding and analgesic activity.
    Melvin LS; Milne GM; Johnson MR; Wilken GH; Howlett AC
    Drug Des Discov; 1995 Nov; 13(2):155-66. PubMed ID: 8872458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A role for cannabinoid receptors, but not endogenous opioids, in the antinociceptive activity of the CB2-selective agonist, GW405833.
    Whiteside GT; Gottshall SL; Boulet JM; Chaffer SM; Harrison JE; Pearson MS; Turchin PI; Mark L; Garrison AE; Valenzano KJ
    Eur J Pharmacol; 2005 Dec; 528(1-3):65-72. PubMed ID: 16316650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of 2-(3,5-difluoro-4-methylsulfonaminophenyl)propanamides as potent TRPV1 antagonists.
    Kim C; Ann J; Lee S; Sun W; Blumberg PM; Frank-Foltyn R; Bahrenberg G; Stockhausen H; Christoph T; Lee J
    Bioorg Med Chem Lett; 2018 Aug; 28(14):2539-2542. PubMed ID: 29884534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis.
    Cabranes A; Venderova K; de Lago E; Fezza F; Sánchez A; Mestre L; Valenti M; García-Merino A; Ramos JA; Di Marzo V; Fernández-Ruiz J
    Neurobiol Dis; 2005 Nov; 20(2):207-17. PubMed ID: 16242629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decahydroquinoline amides as highly selective CB2 agonists: role of selectivity on in vivo efficacy in a rodent model of analgesia.
    Manley PJ; Zartman A; Paone DV; Burgey CS; Henze DA; Della Penna K; Desai R; Leitl MD; Lemaire W; White RB; Yeh S; Urban MO; Kane SA; Hartman GD; Bilodeau MT; Trotter BW
    Bioorg Med Chem Lett; 2011 Apr; 21(8):2359-64. PubMed ID: 21420857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.